Novo Nordisk’s Wegovy (injectable semaglutide) is currently the rage as a treatment option for obesity. But the question on the mind of many in markets like India is when supplies will be available in the country.
Novo Nordisk India corporate vice-president and managing director, Vikrant Shrotriya, made it clear the company would have liked to launch...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?